Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Michelle Haas

Concepts (141)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Latent Tuberculosis
8
2021
70
2.840
Why?
Antitubercular Agents
6
2025
211
1.150
Why?
Isoniazid
4
2025
70
0.890
Why?
Tuberculosis
3
2024
289
0.750
Why?
Tuberculin Test
2
2024
36
0.690
Why?
Interferon-gamma Release Tests
2
2024
32
0.680
Why?
Health Systems Plans
1
2020
3
0.650
Why?
Diagnostic Tests, Routine
1
2019
108
0.560
Why?
Directly Observed Therapy
1
2018
16
0.550
Why?
Rifampin
5
2025
79
0.520
Why?
Mycobacterium Infections
1
2016
55
0.460
Why?
Mass Screening
2
2020
1300
0.440
Why?
AIDS-Related Opportunistic Infections
1
2016
130
0.430
Why?
Receptors, CXCR5
1
2014
29
0.430
Why?
Mycobacterium tuberculosis
1
2018
325
0.430
Why?
Receptors, CXCR4
1
2014
90
0.410
Why?
Lymphoid Tissue
1
2014
82
0.410
Why?
Mycobacterium Infections, Nontuberculous
3
2024
339
0.390
Why?
Proto-Oncogene Proteins c-bcl-2
1
2014
237
0.380
Why?
Nontuberculous Mycobacteria
2
2024
189
0.370
Why?
Drug Administration Schedule
4
2025
782
0.350
Why?
HIV-1
2
2014
911
0.330
Why?
Tuberculosis, Pulmonary
2
2025
127
0.320
Why?
Drug Therapy, Combination
3
2025
1034
0.300
Why?
CD4-Positive T-Lymphocytes
1
2014
1148
0.270
Why?
Emigrants and Immigrants
2
2020
160
0.260
Why?
Refugees
1
2024
83
0.190
Why?
HIV Infections
2
2016
3210
0.190
Why?
Anti-Infective Agents
2
2015
234
0.170
Why?
Anti-Bacterial Agents
4
2024
1935
0.160
Why?
Emigration and Immigration
1
2020
66
0.150
Why?
Humans
21
2025
145625
0.150
Why?
Tuberculin
1
2019
8
0.150
Why?
Georgia
1
2019
79
0.150
Why?
Caliciviridae Infections
1
2019
18
0.140
Why?
Norovirus
1
2019
22
0.140
Why?
Single-Domain Antibodies
1
2019
16
0.140
Why?
United States
5
2024
16041
0.130
Why?
Internal Medicine
1
2020
279
0.130
Why?
Female
14
2025
79080
0.130
Why?
Skin Diseases, Bacterial
2
2015
22
0.130
Why?
Receptors, HIV
2
2014
23
0.130
Why?
Nitrofurantoin
1
2017
9
0.130
Why?
Anti-Infective Agents, Urinary
1
2017
16
0.120
Why?
Cystitis
1
2017
24
0.120
Why?
Fluoroquinolones
1
2017
44
0.120
Why?
Randomized Controlled Trials as Topic
2
2025
1754
0.120
Why?
Escherichia coli
2
2019
831
0.120
Why?
Retrospective Studies
5
2021
17291
0.120
Why?
Pneumonia, Viral
1
2020
387
0.110
Why?
Coronavirus Infections
1
2020
379
0.110
Why?
Enterocolitis, Pseudomembranous
1
2015
29
0.110
Why?
Male
12
2025
73014
0.110
Why?
Adult
8
2025
40821
0.110
Why?
Drug Monitoring
1
2018
399
0.110
Why?
Medication Therapy Management
1
2015
73
0.100
Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2014
43
0.100
Why?
Public Health
1
2019
573
0.100
Why?
Soft Tissue Infections
1
2014
42
0.100
Why?
Healthcare Disparities
1
2020
728
0.100
Why?
Immunophenotyping
1
2014
324
0.100
Why?
Infection Control
1
2015
174
0.100
Why?
Drug Prescriptions
1
2015
290
0.090
Why?
Global Health
1
2016
402
0.090
Why?
Pediatrics
1
2020
1122
0.090
Why?
Middle Aged
8
2025
36359
0.090
Why?
Cross Infection
1
2015
258
0.090
Why?
Pandemics
1
2020
1700
0.090
Why?
Quality Improvement
1
2020
1325
0.090
Why?
ADP-ribosyl Cyclase 1
1
2011
43
0.090
Why?
Infant
3
2020
10093
0.090
Why?
Receptors, CCR5
1
2011
59
0.080
Why?
Anti-HIV Agents
2
2016
914
0.080
Why?
CD4 Antigens
1
2011
135
0.080
Why?
HLA-DR Antigens
1
2011
211
0.080
Why?
Internship and Residency
1
2020
1269
0.080
Why?
Adolescent
5
2025
22451
0.070
Why?
T-Lymphocyte Subsets
1
2011
415
0.070
Why?
Membrane Glycoproteins
1
2011
495
0.070
Why?
Patient Discharge
1
2015
991
0.070
Why?
Lung Diseases
2
2024
787
0.070
Why?
Gene Expression Profiling
1
2014
1790
0.060
Why?
RNA, Viral
1
2011
691
0.060
Why?
Child, Preschool
3
2020
11888
0.060
Why?
Aged
3
2021
26251
0.060
Why?
Health Services Accessibility
1
2015
1101
0.060
Why?
Rifabutin
1
2025
7
0.060
Why?
Pyrazinamide
1
2025
16
0.060
Why?
Nitroimidazoles
1
2025
16
0.060
Why?
Diarylquinolines
1
2025
16
0.060
Why?
Ethambutol
1
2025
27
0.060
Why?
Clinical Trials, Phase II as Topic
1
2025
74
0.060
Why?
Oxazoles
1
2025
48
0.060
Why?
Hospitalization
1
2015
2468
0.050
Why?
Multicenter Studies as Topic
1
2025
413
0.050
Why?
Young Adult
3
2025
14240
0.050
Why?
Child
3
2020
22638
0.040
Why?
Aged, 80 and over
3
2020
8351
0.040
Why?
Program Evaluation
2
2015
945
0.040
Why?
Travel
1
2020
133
0.040
Why?
Blood Group Antigens
1
2019
15
0.040
Why?
Capsid
1
2019
94
0.030
Why?
Capsid Proteins
1
2019
94
0.030
Why?
Colorado
2
2020
4588
0.030
Why?
Needs Assessment
1
2020
403
0.030
Why?
Prevalence
1
2024
2852
0.030
Why?
Infant, Newborn
2
2020
6449
0.030
Why?
Crystallography, X-Ray
1
2019
477
0.030
Why?
Health Status Disparities
1
2020
321
0.030
Why?
Treatment Failure
1
2018
358
0.030
Why?
Epitopes
1
2019
479
0.030
Why?
Cephalosporins
1
2017
45
0.030
Why?
Organizational Policy
1
2017
76
0.030
Why?
Binding Sites
1
2019
1306
0.030
Why?
Drug Resistance, Bacterial
1
2017
185
0.030
Why?
Botswana
1
2015
11
0.030
Why?
Odds Ratio
1
2018
1070
0.030
Why?
National Health Programs
1
2015
23
0.030
Why?
Time
1
2015
85
0.030
Why?
Drug Utilization Review
1
2015
60
0.030
Why?
Drug Resistance, Microbial
1
2015
67
0.030
Why?
Population Surveillance
1
2018
477
0.030
Why?
Hypokalemia
1
2014
23
0.030
Why?
Inappropriate Prescribing
1
2015
66
0.030
Why?
Community-Institutional Relations
1
2015
101
0.030
Why?
Pneumonia, Bacterial
1
2015
114
0.030
Why?
Cohort Studies
1
2024
6045
0.030
Why?
Safety Management
1
2015
130
0.020
Why?
Acute Disease
1
2017
1033
0.020
Why?
Patient Care
1
2015
120
0.020
Why?
Delivery of Health Care, Integrated
1
2017
304
0.020
Why?
Community-Acquired Infections
1
2015
179
0.020
Why?
Drug Combinations
1
2014
399
0.020
Why?
Protein Binding
1
2019
2239
0.020
Why?
Urinary Tract Infections
1
2015
207
0.020
Why?
Ambulatory Care
1
2017
627
0.020
Why?
Risk Assessment
1
2020
3678
0.020
Why?
Practice Guidelines as Topic
1
2017
1581
0.020
Why?
Lymph Nodes
1
2011
511
0.020
Why?
Treatment Outcome
1
2018
11744
0.010
Why?
Risk Factors
1
2014
10840
0.010
Why?
Haas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)